Colloquium Seminar: Theranostics: The future of nuclear medicine
Speaker: Steven Larson, Memorial Sloan Kettering Cancer Center
Location: Auditorium
Time: 14:00
Theranostics is the use of the same molecular moiety for a combination of diagnosis and therapy. Radiotracers lend themselves to theranostics, because it is simply a matter of scaling up the dose, from diagnosis to therapy, in some important instances. A case in point would be the use of 124I for quantitative imaging, staging and diagnosis, in a patient who will subsequently be treated with 131I, for thyroid cancer. Other examples include the use of radiolabeled antibodies such as 124I-3F8 (an anti-GD2, antigen) at a low level for diagnosis, and then scaling up for therapeutic effect. PET imaging, and in some intstaces quantiative SPECT imaging, are the normal diagnostic imaging agents employed.